Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database

• Hauptverfasser: Rachel Prevost (Verfasst von), Basile Chretien (Verfasst von), Elise-Marie Minoc (Verfasst von), Charles Dolladille (Verfasst von), Angélique Da-Silva (Verfasst von), Ahmad Nehme (Verfasst von), Florence Joly (Verfasst von), Véronique Lelong-Boulouard (Verfasst von), Etienne Bastien (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Importance: Endocrine therapies (ETs) and inhibitors of cyclin-dependent kinases-4/6 (iCDK4/6s) are a standard treatment in breast cancer. However, data on potential neurocognitive impacts remain inconsistent for ET and are scarce for iCDK4/6s.Objective: To evaluate whether ET and iCDK4/6s are assoc...